Consequences of interactions between human neutrophils and Staphylococcus aureus

人类中性粒细胞和金黄色葡萄球菌之间相互作用的后果

基本信息

  • 批准号:
    9131612
  • 负责人:
  • 金额:
    $ 38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-09-01 至 2020-02-29
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Human polymorphonuclear leukocytes (PMN) are at the front-line of cellular innate immune-mediated host defense against infection, especially those caused by organisms such as S. aureus (SA). Despite the potent PMN antimicrobial system, 10-20% of ingested SA remained viable, but not replicating, in PMN. Persistence of SA within PMN has profound clinical consequences, as signature features of staphylococcal infection are relapse, metastases, and failure of antibiotics to which SA are susceptible. In our ongoing studies of the fate of SA-laden human PMN and their interactions with monocyte-derived macrophages (MØ), we have made several novel findings: PMN-SA (1) early after phagocytosis of SA display a phenotype that is atypical for pathogen-induced apoptosis; (2) are not efficiently efferocytosed by MØ; (3) maintain sustained levels of proliferating cell nuclear antigen (PCNA), a cell-cycle protein expressed in PMN cytoplasm, and recently linked to prolonging PMN survival by scavenging procaspases; and (4) lyse in a fashion most consistent with necroptosis, a caspase-independent programmed necrotic cell death pathway never previously described in PMN but involving a multicomponent cytoplasmic signaling complex and dependence on receptor-interacting protein kinase 1 (RIP1K). We reason that these cellular events in and between PMN-SA and MØ drive the clinical hallmarks of SA infection and propose studies to explore of the mechanisms underlying our novel observations. Aim 1: Determine the mechanisms underlying the failed efferocytosis of PMN-SA by M¿ 1A: Identify signals generated by PMN-SA that promote efferocytosis by MØ 1B: Identify signals generated by PMN-SA that actively block efferocytosis by MØ 1C: Identify signaling pathways and effector responses of MØ challenged with PMN-SA 1D: Determine the role of ectosomes generated by PMN-SA to modulate efferocytosis by MØ Aim 2: Identify cellular components, biochemical events, and signaling pathways underlying necroptosis of PMN-SA 2A: Determine the composition and regulation of the ripoptosome in PMN-SA 2B: Determine the contribution of PCNA to the initial prolonged survival and eventual lysis of PMN-SA 2C: Determine the signaling pathways engaged as PMN-SA proceed to necroptosis 2D: Determine the role of TNF-dependent signaling in necroptosis of PMN-SA Our studies will identify mechanisms responsible for the atypical apoptosis, failed efferocytosis, and necrotic death of PMN-SA, thereby providing novel insights into fundamental aspects of phagocyte control of the inflammatory response and new potential therapeutic targets.
 描述(申请人提供):人多形核白细胞(PMN)处于细胞天然免疫介导的宿主抵抗感染的第一线,尤其是由金黄色葡萄球菌(SA)等生物引起的感染。尽管PMN有强大的抗菌系统,但摄入的SA中仍有10%-20%在PMN中存活,但不能复制。金黄色葡萄球菌在中性粒细胞中的持续存在具有深远的临床后果,因为金黄色葡萄球菌感染的特征是复发、转移和对金黄色葡萄球菌敏感的抗生素失效。在我们对携带SA的人PMN的命运及其与单核细胞来源的巨噬细胞(M?)相互作用的持续研究中,我们有了一些新的发现:PMN-SA(1)吞噬SA后的早期表现出一种非典型的病原体诱导的细胞凋亡的表型;(2)M?不能有效地吞噬细胞;(3)维持增殖细胞核抗原(PCNA)的持续水平,这是一种在PMN细胞质中表达的细胞周期蛋白,最近与通过清除原酶来延长PMN存活有关;以及(4)以与坏死性下垂最为一致的方式进行裂解,这是一种caspase非依赖性的程序性坏死性细胞死亡途径,以前从未在PMN中描述过,但涉及一个多组分的细胞质信号复合体和依赖于受体相互作用的蛋白激酶1(RIP1K)。我们推断,PMN-SA和M?之间的这些细胞事件驱动了SA感染的临床特征,并建议进行研究,以探索我们新观察到的机制。目的1:确定PMN-SA泡腾失败的机制1A:确定PMN-SA产生的促进M?1B泡腾的信号:确定PMN-SA产生的积极阻断M?1C泡腾的信号:确定PMN-SA 1D攻击M?的信号通路和效应反应:确定PMN-SA产生的胞外体在M?调节泡腾作用中的作用目标2:确定细胞成分、生化事件、中性粒细胞-SA 2B中核糖体的组成和调节:确定增殖细胞核抗原在中性粒细胞-SA 2C最初延长存活和最终溶解中的作用:确定中性粒细胞-SA进入坏死下垂过程中的信号通路2D:确定肿瘤坏死因子依赖信号在中性粒细胞-SA坏死症中的作用我们的研究将确定中性粒细胞-SA的非典型凋亡、泡泡失败和坏死性死亡的机制,从而为炎症反应的吞噬细胞控制的基本方面和新的潜在治疗靶点提供新的见解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

William M. Nauseef其他文献

Neutrophil dysfunction in the pathogenesis of cystic fibrosis
中性粒细胞功能障碍在囊性纤维化发病机制中的作用
  • DOI:
    10.1182/blood.2021014699
  • 发表时间:
    2022-04-28
  • 期刊:
  • 影响因子:
    23.100
  • 作者:
    Guoshun Wang;William M. Nauseef
  • 通讯作者:
    William M. Nauseef
Insights into myeloperoxidase biosynthesis from its inherited deficiency
  • DOI:
    10.1007/s001090050265
  • 发表时间:
    1998-08-26
  • 期刊:
  • 影响因子:
    4.200
  • 作者:
    William M. Nauseef
  • 通讯作者:
    William M. Nauseef
755: Neutrophil Stimulation with Mycobacterium Bovis Bacillus Calmette-Guérin (BCG) Results in the Upregulation of Surface-Bound and Soluble Functional TRAIL/APO-2L
  • DOI:
    10.1016/s0022-5347(18)34924-3
  • 发表时间:
    2005-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Thomas S. Griffith;Troy J. Kemp;Aaron T. Ludwig;James K. Earel;Jill M. Moore;Bonita Moses;William M. Nauseef
  • 通讯作者:
    William M. Nauseef
Immunochemical and Electrophoretic Analyses of Phosphorylated Native and Recombinant Neutrophil Oxidase Component p47-<em>Phox</em>
  • DOI:
    10.1182/blood.v76.12.2622.2622
  • 发表时间:
    1990-12-15
  • 期刊:
  • 影响因子:
  • 作者:
    William M. Nauseef;Bryan D. Volpp;Robert A. Clark
  • 通讯作者:
    Robert A. Clark

William M. Nauseef的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('William M. Nauseef', 18)}}的其他基金

Determinants of human neutrophil fate after phagocytosis
吞噬作用后人类中性粒细胞命运的决定因素
  • 批准号:
    10092904
  • 财政年份:
    2018
  • 资助金额:
    $ 38万
  • 项目类别:
Determinants of human neutrophil fate after phagocytosis
吞噬作用后人类中性粒细胞命运的决定因素
  • 批准号:
    10328225
  • 财政年份:
    2018
  • 资助金额:
    $ 38万
  • 项目类别:
Consequences of interactions between human neutrophils and Staphylococcus aureus
人类中性粒细胞和金黄色葡萄球菌之间相互作用的后果
  • 批准号:
    9230328
  • 财政年份:
    2015
  • 资助金额:
    $ 38万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    8305638
  • 财政年份:
    2011
  • 资助金额:
    $ 38万
  • 项目类别:
Early airway innate immune responses to F. tularensis
对土拉弗朗西斯菌的早期气道先天免疫反应
  • 批准号:
    8305636
  • 财政年份:
    2011
  • 资助金额:
    $ 38万
  • 项目类别:
Early airway innate immune responses to F. tularensis
对土拉弗朗西斯菌的早期气道先天免疫反应
  • 批准号:
    7920676
  • 财政年份:
    2010
  • 资助金额:
    $ 38万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    7920682
  • 财政年份:
    2010
  • 资助金额:
    $ 38万
  • 项目类别:
Human neutrophils, phospholipase A2 and S.aureus: microbial targets and responses
人中性粒细胞、磷脂酶 A2 和金黄色葡萄球菌:微生物靶标和反应
  • 批准号:
    8195608
  • 财政年份:
    2009
  • 资助金额:
    $ 38万
  • 项目类别:
Human neutrophils, phospholipase A2 and S.aureus: microbial targets and responses
人中性粒细胞、磷脂酶 A2 和金黄色葡萄球菌:微生物靶标和反应
  • 批准号:
    7791569
  • 财政年份:
    2009
  • 资助金额:
    $ 38万
  • 项目类别:
Human neutrophils and Staphylcoccus aureus: microbial targets and responses
人类中性粒细胞和金黄色葡萄球菌:微生物靶标和反应
  • 批准号:
    8762232
  • 财政年份:
    2009
  • 资助金额:
    $ 38万
  • 项目类别:

相似海外基金

SBIR Phase II: Development of a urine dipstick test that can guide immediate and appropriate antibiotic therapy for treatment of complicated urinary tract infections
SBIR II 期:开发尿液试纸测试,可以指导复杂尿路感染的立即和适当的抗生素治疗
  • 批准号:
    2213034
  • 财政年份:
    2023
  • 资助金额:
    $ 38万
  • 项目类别:
    Cooperative Agreement
Personalized Antibiotic Therapy in the Emergency Department: PANTHER Trial
急诊科的个性化抗生素治疗:PANTHER 试验
  • 批准号:
    10645528
  • 财政年份:
    2023
  • 资助金额:
    $ 38万
  • 项目类别:
Strategies for improving the efficacy of combinatorial antibiotic therapy in chronic infections
提高慢性感染联合抗生素治疗疗效的策略
  • 批准号:
    10736285
  • 财政年份:
    2023
  • 资助金额:
    $ 38万
  • 项目类别:
A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures
一种治疗感染性骨折的新型骨靶向抗生素疗法
  • 批准号:
    10603486
  • 财政年份:
    2023
  • 资助金额:
    $ 38万
  • 项目类别:
Severe Cutaneous Adverse Reactions Following Outpatient Antibiotic Therapy: A Population-based Study
门诊抗生素治疗后的严重皮肤不良反应:一项基于人群的研究
  • 批准号:
    449379
  • 财政年份:
    2020
  • 资助金额:
    $ 38万
  • 项目类别:
    Studentship Programs
Sex-Specific Differences in End-of-Life Burdensome Interventions and Antibiotic Therapy in Nursing Home Residents With Advanced Dementia
患有晚期痴呆症的疗养院居民的临终干预和抗生素治疗的性别差异
  • 批准号:
    422034
  • 财政年份:
    2020
  • 资助金额:
    $ 38万
  • 项目类别:
Optimizing outpatient parenteral antibiotic therapy to support hospital-in-the-home program across the unique environmental conditions of Australia
优化门诊肠外抗生素治疗,以支持澳大利亚独特环境条件下的家庭医院计划
  • 批准号:
    nhmrc : 1197866
  • 财政年份:
    2020
  • 资助金额:
    $ 38万
  • 项目类别:
    Investigator Grants
Resistance evolution in the presence of combination antibiotic therapy
联合抗生素治疗下耐药性的演变
  • 批准号:
    2241853
  • 财政年份:
    2019
  • 资助金额:
    $ 38万
  • 项目类别:
    Studentship
Host-pathogen interactions in antibiotic therapy for listeriosis
李斯特菌病抗生素治疗中宿主与病原体的相互作用
  • 批准号:
    18K07106
  • 财政年份:
    2018
  • 资助金额:
    $ 38万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Multipurpose targeted nano-antibiotic therapy to fight tough infection in bones
多用途靶向纳米抗生素疗法可对抗骨骼中的严重感染
  • 批准号:
    9788269
  • 财政年份:
    2018
  • 资助金额:
    $ 38万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了